2.50
Hdl Handle:
http://hdl.handle.net/10755/164780
Category:
Abstract
Type:
Presentation
Title:
SELF-REPORTED ADHERENCE TO ERLOTINIB BY ELDERS WITH LUNG CANCER
Author(s):
Morse, Linda; Lucca, Joan; Ostler, Pat
Author Details:
Linda Morse, RN, MSN, Clinical Trial Nurse, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, email: lmorse2@partners.org; Joan Lucca, RN, NP, AOCN; Pat Ostler, RN, BSN, MHS, Massachusetts General Hsptl., Boston, Massachusetts
Abstract:
Research Study: The majority of oncologic, molecularly targeted drugs being studied and FDA-approved are oral agents. Promoting and facilitating accurate administration of investigational agents is a major responsibility of the clinical trial nurse (CTN). Research related to adherence is a key priority in the 2005-2009 Oncology Nursing Society's Research Agenda. The goals are to determine adherence rates and factors associated with non-adherence, describe the CTNÆs role in facilitating adherence to oral cancer regimens, and assess the feasibility of developing a nursing role for the support of patients receiving oral agents outside of research protocols. This retrospective research project will review adherence data from an 80-subject clinical trial of erlotinib, for chemotherapy-naive, elderly (>70 years old) patients with advanced non-small cell lung cancer. This investigator-initiated study was conducted at Dana-Farber/ Harvard Cancer Center. The framework for nursing practice in our institution is the Synergy Model which has as one of its core nursing competencies, the ability of the nurse to facilitate patient learning. Facilitation of learning is one of several competencies derived from patient needs or characteristics. The CTN met with the study participants during monthly clinic visits for trial-related education and assessment. Patients documented self-administration of erlotinib in a drug accountability log that the CTN examined and campared with the amount of returned drug. Discrepancies were discussed with the patient and documented. Accountability logs will be retrospectively examined. Self-reported adherence rates and reasons for discrepancies in pill accountability will be compiled and reviewed to identify factors/barriers related to adherence. The role of the CTN in adherence will be evaluated. The review of patient records is ongoing and our analysis of adherence in this clinical trial will be presented. In addition, we will provide an assessment of the CTN's role in the study and the feasibility of developing a similar nursing role when oral cancer drugs are prescribed outside of a research protocol.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2009
Conference Name:
34th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
San Antonio, Texas, USA
Sponsors:
Funding Source: Genentech, Inc.
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleSELF-REPORTED ADHERENCE TO ERLOTINIB BY ELDERS WITH LUNG CANCERen_GB
dc.contributor.authorMorse, Lindaen_US
dc.contributor.authorLucca, Joanen_US
dc.contributor.authorOstler, Paten_US
dc.author.detailsLinda Morse, RN, MSN, Clinical Trial Nurse, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, email: lmorse2@partners.org; Joan Lucca, RN, NP, AOCN; Pat Ostler, RN, BSN, MHS, Massachusetts General Hsptl., Boston, Massachusettsen_US
dc.identifier.urihttp://hdl.handle.net/10755/164780-
dc.description.abstractResearch Study: The majority of oncologic, molecularly targeted drugs being studied and FDA-approved are oral agents. Promoting and facilitating accurate administration of investigational agents is a major responsibility of the clinical trial nurse (CTN). Research related to adherence is a key priority in the 2005-2009 Oncology Nursing Society's Research Agenda. The goals are to determine adherence rates and factors associated with non-adherence, describe the CTNÆs role in facilitating adherence to oral cancer regimens, and assess the feasibility of developing a nursing role for the support of patients receiving oral agents outside of research protocols. This retrospective research project will review adherence data from an 80-subject clinical trial of erlotinib, for chemotherapy-naive, elderly (>70 years old) patients with advanced non-small cell lung cancer. This investigator-initiated study was conducted at Dana-Farber/ Harvard Cancer Center. The framework for nursing practice in our institution is the Synergy Model which has as one of its core nursing competencies, the ability of the nurse to facilitate patient learning. Facilitation of learning is one of several competencies derived from patient needs or characteristics. The CTN met with the study participants during monthly clinic visits for trial-related education and assessment. Patients documented self-administration of erlotinib in a drug accountability log that the CTN examined and campared with the amount of returned drug. Discrepancies were discussed with the patient and documented. Accountability logs will be retrospectively examined. Self-reported adherence rates and reasons for discrepancies in pill accountability will be compiled and reviewed to identify factors/barriers related to adherence. The role of the CTN in adherence will be evaluated. The review of patient records is ongoing and our analysis of adherence in this clinical trial will be presented. In addition, we will provide an assessment of the CTN's role in the study and the feasibility of developing a similar nursing role when oral cancer drugs are prescribed outside of a research protocol.en_GB
dc.date.available2011-10-27T12:06:52Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:06:52Z-
dc.conference.date2009en_US
dc.conference.name34th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationSan Antonio, Texas, USAen_US
dc.description.sponsorshipFunding Source: Genentech, Inc.-
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.